Study guide
1.3 Preventive Health, Immunization & Well-Patient Screening
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
1.3 Preventive Health, Immunization & Well-Patient Screening
Key Takeaways Explain This Topic AI
USPSTF cancer screening guidelines recommend biennial mammography for women aged 40–74, and cervical cancer screening for women aged 21–65 (cytology every 3 years for 21–29; cytology every 3 years or hrHPV co-testing/alone every 5 years for 30–65).
USPSTF colorectal cancer screening is recommended for adults aged 45–75 (colonoscopy every 10 years or FIT annually); annual low-dose CT lung cancer screening is indicated for adults aged 50–80 with a >=20 pack-year smoking history who currently smoke or quit within 15 years.
Cardiovascular primary prevention includes one-time abdominal aortic aneurysm (AAA) ultrasound for men aged 65–75 who ever smoked, and primary statin therapy for adults aged 40–75 with >=1 risk factor and 10-year ASCVD risk >=10%.
Adult immunizations include annual influenza vaccine, pneumococcal vaccination (PCV20 or PCV15+PPSV23) for adults >=65 or with risk factors, 2-dose Recombinant Zoster Vaccine for adults >=50, and Tdap booster every 10 years (and during every pregnancy at 27–36 weeks).
Osteoporosis DEXA bone density screening is recommended for all women aged >=65 (or younger postmenopausal women with elevated FRAX risk); a T-score <= -2.5 defines osteoporosis.
Last updated: July 2026
Evidence-Based Preventive Health Screening
Preventive medicine focuses on reducing disease incidence (primary prevention) and detecting asymptomatic disease early to improve clinical outcomes (secondary prevention). The United States Preventive Services Task Force (USPSTF) assigns letter grades (A, B, C, D, I) to preventive interventions. Grade A and B recommendations are high-yield standards tested extensively on the USMLE Step 2 CK.
USPSTF Cancer Screening Recommendations
Malignancy Target Population Screening Modality & Interval Discontinuation Criteria
Breast Cancer Women aged 40–74 years Biennial (every 2 years) screening mammography Age >=75 years, or life expectancy <10 years
Cervical Cancer Women aged 21–65 years 21–29 yrs : Cervical cytology (Pap) every 3 years.; 30–65 yrs : Cytology every 3 yrs, OR hrHPV co-testing every 5 yrs, OR hrHPV alone every 5 yrs. Age >65 yrs with adequate prior negative screening; hysterectomy with cervix removal for benign disease
Colorectal Cancer Adults aged 45–75 years Colonoscopy every 10 yrs, OR FIT (Fecal Immunochemical Test) annually, OR sDNA-FIT (Cologuard) every 1–3 yrs, OR CT colonography every 5 yrs. Age 76–85 yrs (individualized based on health status); discontinue at age >85 yrs
Lung Cancer Adults aged 50–80 years with >=20 pack-year smoking history Annual low-dose computed tomography (LDCT) of the chest Quit smoking >=15 years ago, or develops health problem limiting life expectancy/surgical candidacy
Prostate Cancer Men aged 55–69 years Individualized PSA-based screening (Grade C recommendation) Age >=70 years
Cardiovascular and Metabolic Risk Screening
Cardiovascular disease and diabetes mellitus screening enables early pharmacological and lifestyle interventions to prevent target organ damage.
Screening Parameters & Indications
Disease Entity Target Population Screening Parameter / Modality Clinical Thresholds & Action
Abdominal Aortic Aneurysm (AAA) Men aged 65–75 years who have ever smoked (>=100 cigarettes lifetime) One-time abdominal ultrasound Repair considered if AAA diameter >=5.5 cm or expanding >0.5 cm in 6 months
Hypertension (HTN) Adults aged >=18 years Office blood pressure measurement (confirm with out-of-office ABPM/HBPM) BP >=130/80 mmHg defines stage 1 HTN (ACC/AHA guidelines)
Type 2 Diabetes Mellitus Adults aged 35–70 years who are overweight/obese (BMI >=25 kg/m²; >=23 in Asian Americans) Fasting plasma glucose, HbA1c, or 2-hour oral glucose tolerance test (OGTT) Fasting glucose >=126 mg/dL , HbA1c >=6.5% , or 2-hr OGTT >=200 mg/dL establishes T2DM diagnosis
Lipid Screening / Statin Therapy Adults aged 40–75 years without history of CVD Fasting lipid panel; calculate 10-year ASCVD risk score Initiate moderate-intensity statin if patient has >=1 CVD risk factor (HTN, DM, smoking, dyslipidemia) AND 10-yr ASCVD risk >=10%
Osteoporosis Women aged >=65 years (or postmenopausal women <65 with elevated FRAX risk) Dual-energy X-ray absorptiometry ( DEXA ) scan at femoral neck/lumbar spine T-score <= -2.5 defines osteoporosis; T-score between -1.0 and -2.49 defines osteopenia
Adult Immunization Schedules and Special Populations
Vaccination is a cornerstone of primary prevention. ACIP guidelines establish routine schedules and high-risk indications.
Summary of High-Yield Adult Vaccines
Vaccine Target Population & Schedule Special Risk Groups & Contraindications
Influenza Annual dose for all individuals >=6 months of age Inactivated (IIV) or Recombinant (RIV) for age >=65; Live Attenuated (LAIV, intranasal) is contra-indicated in immunocompromised, pregnant, or age >=50
Pneumococcal Adults >=65 years , or adults 19–64 years with risk factors (chronic heart/lung/liver disease, DM, smoking, alcoholism, asplenia, immunocompromise) Option A : Single dose of PCV20 alone.; Option B : PCV15 followed by PPSV23 >=1 year later (>=8 weeks later for asplenia/immunocompromise)
Varicella-Zoster (Shingrix) Recombinant Zoster Vaccine (RZV) 2-dose series for adults >=50 years (given 2–6 months apart) Indicated regardless of prior herpes zoster episode or prior live zoster (Zostavax) vaccination; non-live vaccine safe in immunocompromised
Tetanus, Diphtheria, Pertussis Tdap single dose once for all adults, then Td or Tdap booster every 10 years Administer 1 dose of Tdap during EVERY pregnancy between 27 and 36 weeks gestation (regardless of prior Tdap history)
Human Papillomavirus (HPV) Routine at age 11–12; catch-up through age 26 years for all adults (shared decision-making for ages 27–45) 2-dose series if started before age 15; 3-dose series (0, 1–2, 6 months) if started at age >=15 or in immunocompromised patients
Hepatitis B All adults aged 19–59 years (and adults >=60 with risk factors) 3-dose series (Engerix-B, Recombivax HB) or 2-dose series (Heplisav-B); screen for HBsAg, anti-HBs, anti-HBc in high-risk patients
- Behavioral Health & Well-Patient Screening Algorithm [ Routine Adult Well-Patient Visit ]
- |
- +--------------------------+--------------------------+
- | |
- [ Depression Screening: PHQ-2 ] [ Alcohol Screening: AUDIT-C / CAGE ]
- (Little interest + Feeling down) (Frequency, quantity, binge drinking)
- | |
- +-----+-----+ +-----+-----+
- | | | |
- [ Negative ] [ Positive (>=1) ] [ Negative ] [ Positive (>=3 M, >=2 F) ]
- | | | |
- Continue Administer **PHQ-9** Continue Administer full **AUDIT**
- routine - Score >=10: Major Depression routine - Brief behavioral counseling
- care - Assess suicidal ideation care - Pharmacotherapy if AUD
- (Naltrexone, Acamprosate)
- Clinical Management Rules
Universal Depression Screening : USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women, using the PHQ-2 followed by the PHQ-9.
Unhealthy Alcohol Use : Screen all adults >=18 years using AUDIT-C or single-question screening ("How many times in the past year have you had 5 [for men] or 4 [for women] or more drinks in a day?"). Provide brief behavioral counseling interventions to patients engaging in risky or hazardous drinking.